A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma

Chen, Shujia; Liu, Peiyan; Zhao, Lili; Han, Ping; Liu, Jie; Yang, Hang; Li, Jia

doi:10.3389/fimmu.2022.954653

Cited by 27 publications

(25 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang et al reported that a cuproptosis-related lncRNA signature can predict HCC patient prognosis and responsiveness to immune checkpoint blockade therapy, such as AC099329.2, AC138904.1, GIHCG and DNMBP-AS1 [26]. Subsequently, several researchers also constructed another set of cuproptosis-related lncRNA signature prognosis model for HCC patients, including MIR210HG, AC099850.3, AL031985.3, AC012073.1, MKLN1-AS, KDM4A-AS1, LINC01515, HCG15, MKLN1-AS, AL122035.1, and so on [27][28][29]. These findings indicated that cuproptosis-related noncoding RNAs might be involved in HCC via bioinformatics tools.…”

Section: Discussionmentioning

confidence: 99%

A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients

Bai¹,

Liu

et al. 2022

World J Oncol

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancers, with more than a million cases per year by 2025. Cuproptosis is a novel form of programmed cell death, and is caused by mitochondrial lipoylation and destabilization of iron-sulfur proteins triggered by copper, which was considered as a key player in various biological processes. However, the roles of cuproptosisrelated genes (CRGs) in HCC remain largely unknown. Methods:In the present study, we constructed and validated a four CRGs signature for predicting the overall survival (OS) of HCC patients in both The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases. Results:Patients with high CRGs risk score showed shorter OS than those with low CRGs risk score. Functional analysis suggested that the CRGs-based prognostic signature was associated with metabolism remodeling which facilitated liver cancer progression. In addition, reduced infiltration of CD8 + T cells and increased macrophages were found in HCCs from patients with high CRGs risk score. As one of the four CRGs, higher expression of dihydrolipoamide Sacetyltransferase (DLAT) was accompanied by higher expression of program death ligand 1 (PD-L1) in HCC. Further, we confirmed that DLAT was up-regulated and correlated with poor prognosis in a clinical HCC cohort. Conclusion:In conclusion, our study constructed a four CRGs signature prognostic model and identified DLAT as an independent prognostic factor for HCC, thus providing new clues for understanding the association between cuproptosis and HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients

Bai¹,

Liu

et al. 2022

World J Oncol

View full text Add to dashboard Cite

show abstract

“…Similarly, there have been some advances in the prognostic study of cuproptosis in tumors such as breast carcinoma and uterine corpus endometrial carcinoma ( Chen, 2022 ; Sha et al, 2022 ). Although in previous studies, the prognostic characteristics and immune response of cuproptosis-related lncRNAs in HCC have also been investigated ( Zhang et al, 2022a ; Zhang et al, 2022b ; Chen et al, 2022 ), and the prognostic value of CRGs in HCC has also been correspondingly investigated ( Zhang et al, 2022c ; Liu et al, 2022 ). However, the research on the relationship between CRGs and immunity needs further study.…”

Section: Introductionmentioning

confidence: 99%

Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma

Zhou

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the world’s malignant tumors with high morbidity and mortality. Cuproptosis is a novel form of cell death. However, the prognostic evaluation and immune relevance of cuproptosis-related genes (CRGs) in HCC are largely unknown. In our study, we constructed a prognostic model of CRGs in HCC and performed immune infiltration, functional analysis, immune checkpoint and drug sensitivity analysis. Systematically elaborated the prognostic and immune correlation of CRGs in HCC. The results showed that 15 CRGs were up-regulated or down-regulated in HCC, and the mutation frequency of CRGs reached 10.33% in HCC, with CDKN2A having the highest mutation frequency. These 19 CRGs were mainly involved in the mitochondrion, immune response and metabolic pathways. Five selected genes (CDKN2A, DLAT, DLST, GLS, PDHA1) were involved in constructing a prognostic CRGs model that enables the overall survival in HCC patients to be predicted with moderate to high accuracy. Prognostic CRGs, especially CDKN2A, the independent factor of HCC prognosis, may be closely associated with immune-cell infiltration, tumor mutation burden (TMB), microsatellite instability(MSI), and immune checkpoints. CD274, CTLA4, LAG3, PDCD1, PDCD1LG2 and SIGLEC15 may be identified as potential therapeutic targets and CD274 correlated highly with prognostic genes. Quantitative Real-Time PCR (qRT-PCR) and immunohistochemical were performed to validate the mRNA and protein expression levels of CDKN2A in adjacent normal tissues and HCC tissues, and the results were consistent with gene difference analysis. In conclusion, CRGs, especially CDKN2A, may serve as potential prognostic predictors in HCC patients and provide novel insights into cancer therapy.

show abstract

“…Previous studies have showed that cuproptosis related lncRNAs were closely associated with head and neck squamous cell cancer [18], hepatocellular carcinoma [19], colon adenocarcinoma [20], and glioma [21]. However, the correlation between cuproptosis related lncRNAs and ESCA remains unclear.…”

Section: Discussionmentioning

confidence: 99%

A novel cuproptosis-related LncRNA signature predicts prognosis inpatients with esophageal carcinoma

Shang

Min

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Esophageal cancer (ESCA) is a significant cause of tumor-related mortality worldwide. Cuproptosis is a novel cell death which is different from other regulate cell death, including ferroptosis, pyroptosis and apoptosis. However, the role of cuproptosis in the initiation and progression of ESCA remains unknown. Methods: The transcriptome data and clinical data of 173 patients with esophageal cancer in TCGA database were sorted and extracted with Perl software. Pearson correlation analysis was performed on cuproptosis related genes and all lncRNAs. The prognostic related lncRNAs were determined by univariate and multivariate Cox regression analysis, and a new prognostic model was constructed to calculate the risk score of each patient. C-Index curve, PCA analysis and ROC curve analysis were used to evaluate the prognosis prediction performance of 3- cuproptosis related lncRNAs (CRLs) model. In addition, multivariate Cox analysis was used to assess the prognostic value of the model in the entire cohort and in different subgroups. Results: The 3-CRLs risk scoring criteria including EWSAT1, AC125437.1 and GK-IT1 was established to evaluate the overall survival (OS) of ESCA. Survival analysis and ROC curve showed that the score had good prediction performance in TCGA train group and test group. The coefficients of each lncRNAs were analyzed using Lasso regression and lambda values were determined. principal component analysis was used to determine whether 3-CRLs can clearly distinguish the gap between high and low risk samples. Multivariate Cox regression showed that 3-CRLs characteristics were independent prognostic factors of OS. Norman map showed robust effectiveness in prognosis prediction. Conclusion: The risk characteristics based on 3-CRLs may be used to predict the prognosis of esophageal carcinoma patients

show abstract

A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma

Cited by 27 publications

References 54 publications

A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients

A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients

Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma

A novel cuproptosis-related LncRNA signature predicts prognosis inpatients with esophageal carcinoma

Contact Info

Product

Resources

About